Assessment on the Efficacy and Safety of Aidi Injection Combined with Vinorelbine and Cisplatin for Treatment of Advanced Nonsmall Cell Lung Cancer

Zhao, Hua-Ye; Zhou, Haiyan; Wang, Yanting; Chen, Wei; Qi, Shuya; Cao, Junling; Li, Guohui

doi:10.4103/0366-6999.178016

Cited by 11 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 27 systematic reviews/meta-analyses included in our study were published between 2009 and 2020. Of these, 12 of them were published in English language [7][8][9][10][11][12][13][14][15][16][17][18], and the remaining 15 were published in Chinese language [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]. The tumor types including lung cancer, colorectal cancer, malignant lymphoma, hepatic carcinoma, gastric carcinoma, and ovarian cancer.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…The outcomes investigated included tumor response, survival, QOL, and adverse effects. Regarding the quality assessment tool, a total of 21 systematic reviews/meta-analyses used Cochrane RoB tool [7,8,[10][11][12][13][15][16][17][18][19][20][22][23][24][25][26][28][29][30]33], 3 systematic reviews/meta-analyses used the Jadad score [21,27,32], 1 study used both Cochrane RoB tool and Jadad score [31], and 1 meta-analysis used both Cochrane RoB and methodological section of CONSORT statement to evaluate the quality of the included RCTs [14]. But one meta-analysis have not presented the details of quality assessment [9].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Aidi injection combined with chemotherapy in the treatment of cancer patients: a systematic review of systematic reviews and meta-analyses

et al. 2021

View full text Add to dashboard Cite

The objective of the study was to evaluate and summarize the evidence from systematic reviews and meta-analyses regarding the efficacy and safety of Aidi injection combined with chemotherapy in the treatment of cancer patients. PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Chong qing VIP databases, and Wanfang databases were searched for systematic reviews/meta-analyses on the topic of Aidi treating cancer patients published from inception to 20 December 2020. Google Scholar and OpenGrey were searched for grey literature and International Prospective Register of Systematic Reviews for ongoing reviews. Two investigators independently selected eligible studies, extracted data, and assessed the methodological quality of included systematic reviews/meta-analyses using the measurement tool to assess systematic reviews 2 (AMSTAR-2) tool, and the strength of evidence was assessed with the grade of recommendation, assessment, development, and evaluation (GRADE) system. Twenty-seven systematic reviews/meta-analyses were identified in the study. The methodological quality of all 27 systematic reviews/meta-analyses were critically low when evaluated by AMSTAR-2, and the evidence quality of all outcomes rated as either low or very low based on the GRADE system. The available evidence is currently insufficient to support or refute the use of Aidi in the treatment of cancer patients, thus high-quality trials with large sample sizes are needed to explore its efficacy and safety in cancer patients.

show abstract

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Aidi injection combined with chemotherapy in the treatment of cancer patients: a systematic review of systematic reviews and meta-analyses

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Anti-cancer medicine injection is mainly used as an adjuvant radiotherapy and chemotherapy for tumors, with the functions of reducing toxicity, improving symptoms, and enhancing therapeutic efficacy, etc. ( Cheng and Liu, 2009 ; Zhao et al, 2016 ). Numerous clinical studies have found that Chinese medicine treatment of tumors, especially the application of Chinese medicine after radiotherapy and chemotherapy, can not only improve the therapeutic effect but also alleviate the adverse effects caused by radiotherapy and chemotherapy; therefore, Chinese medicine is widely used in the comprehensive treatment of tumors ( Luo et al, 2010 ).…”

Section: Introductionmentioning

confidence: 99%

Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis

Liu

Zhang

2022

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: The aim of the present Bayesian network meta-analysis (NMA) was to explore the comparative effectiveness and safeaty of different Chinese Medicine injections (CMIs) combined with the XELOX regimen versus XELOX alone for colorectal cancer (CRC).Methods: A comprehensive search for randomized controlled trials (RCTs) was performed with regard to different CMIs for the treatment of CRC in several electronic databases up to April 2022. The quality assessment of the included RCTs was conducted according to the Cochrane risk of bias tool. Standard pair-wise and Bayesian NMA were designed to comparethe effectiveness and safety of different CMIs combined with the XELOX regimen by utilizing R 4.0.3 software and Stata 15.1 software simultaneously.Results: Initially, a total of 4296 citations were retrieved through comprehensive searching, and 32 eligible articles involving 2847 participants and 11 CMIs were ultimately included. CMIs combined with XELOX were superior to the XELOX regimen alone, and a total of ten Observation Indicators were included in the study, with the following results. Among all the injections, Shengmaiyin, Shenmai, and Kanglaite combined with the XELOX regimen were the three CMIs with the highest clinical efficiency. The top three in terms of improving CD3+ values were Shengmaiyin, Shenqifuzheng, and Cinobufacini injections. Shenqifuzheng, Shengmaiyin, and BruceaJavanica oil injections combined with the XELOX regimen performed best at raising CD4+ values. Kanglaite, Cinobufacini, and Matrine injections combined with the XELOX regimen performed best in improving CD4+/CD8+ rates. The top three in terms of improving performance status were Xiaoaiping, Shenmai, and Kanglaite injections. Cinobufacini and Brucea Javanica oil injections combined with the XELOX regimen performed best at raising CD8+ values. Shenqifuzheng, Kangai, and Matrine injections combined with the XELOX regimen performed best in improving Gastrointestinal reactions.The top threein terms of improving Leukopenia were Shenqifuzheng, Compound Kushen and Kanglaite injections. The top three in terms of improving Platelet decline were Compound Kushen, Cinobufacini and Shenqifuzheng injections. Additionally, those that were best at improving nausea and vomitting were Cinobufacini, Compound Kushen and Aidi injections.Conclusion: The results of the analysis demonstrated thatShengmaiyin, Kanglaite, and Cinobufacini injections and the XELOX regimen were associated with morepreferable and beneficial outcomes than other CMI groups. Nevertheless, additional results from multicenter trials and high-quality studies will bevital to support our findings.Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=326097, CRD42022326097.

show abstract

“…These are purported to induce tumor cell apoptosis and to inhibit tumor cell proliferation and invasion (Duan et al, 2018b;Chen et al, 2019;Li et al, 2019), to reduce chemotherapy-related ADRs through anti-inflammation and antioxidative stress (Farag et al, 2019;Qu et al, 2019;Zhang et al, 2019), and to repair the host's antitumor immunity though upregulating the levels of peripheral blood lymphocytes (PBLs) (Li et al, 2018;Zhou et al, 2018;Huang et al, 2019). In clinic, Aidi in combination with GP has been widely used in the treatment of NSCLC (Lv et al, 2018;Zhang, 2018;Zhou, 2018;Liu et al, 2019). According to the Cochrane systematic evaluation, three studies (Yang and Ding, 2012;Han et al, 2016;Xiao et al, 2017) including 36 trials evaluated the clinical efficacy and safety of Aidi injection with GP.…”

Section: Introductionmentioning

confidence: 99%

The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non–small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials

et al. 2021

View full text Add to dashboard Cite

Introduction: Aidi injection (Aidi) is composed of cantharidin, astragaloside, ginsenoside, and elentheroside E. As an important adjuvant therapy, Aidi in combination with gemcitabine and cisplatin (GP) is often used in the treatment of non-small cell lung cancer (NSCLC).Objectives: We performed a new evaluation to demonstrate the clinical efficacy and safety of the Aidi and GP combination and further explored an optimal strategy for achieving an ideal response and safety level in advanced NSCLC.Methodology: We collected all the related trials from Chinese and English-language databases, analyzed their methodological bias risk using the Cochrane evaluation Handbook for Systematic Reviews of Interventions Version 5.1.0, extracted all the data using a predefined data extraction form, pooled the data using a series of meta-analyses, and finally summarized the quality of evidence using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach.Results: We included 70 trials with 5,509 patients. Compared with GP alone, the Aidi and GP combination showed a significant improvement in the objective response rate (ORR) [1.82 (1.62–2.04)], disease control rate (DCR) [2.29 (1.97–2.67)], and quality of life (QOL) [3.03 (2.55–3.60)] and a low incidence of hematotoxicity and gastrointestinal and hepatorenal toxicity. Aidi might be more suitable for patients who are first-treated, elderly, or patients with a Karnofsky Performance Status (KPS) score ≥ 60 or anticipated survival time (AST) ≥3 months. An Aidi (50 ml/day, 7–14 days/cycle for one to two cycles), gemcitabine (1000 mg/m2), and cisplatin (20–30 mg/m2, 40–50 mg/m2, or 60–80 mg/m2) might be an optimal regimen for realizing an ideal response and safety level. Most results were robust and of moderate quality.Conclusion: Current evidence indicates that Aidi's value in adjuvant chemotherapy may be broad-spectrum, not just for some regimens. The Aidi and GP combination may show a good short-term response, antitumor immunity, and safety level in patients with NSCLC. Aidi (50 ml/day, 7–14 days/cycle for one and two cycles) with GEM (1000 mg/m2) and DDP (20–30 mg/m2 or 40–50 mg/m2) may be an optimal regimen for realizing an ideal goal in patients who are first-treatment, elderly, or have a KPS score ≥ 60 or AST≥3 months.

show abstract

Assessment on the Efficacy and Safety of Aidi Injection Combined with Vinorelbine and Cisplatin for Treatment of Advanced Nonsmall Cell Lung Cancer

Cited by 11 publications

References 6 publications

Aidi injection combined with chemotherapy in the treatment of cancer patients: a systematic review of systematic reviews and meta-analyses

Aidi injection combined with chemotherapy in the treatment of cancer patients: a systematic review of systematic reviews and meta-analyses

Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis

The Optimal Adjuvant Strategy of Aidi Injection With Gemcitabine and Cisplatin in Advanced Non–small Cell Lung Cancer: A Meta-analysis of 70 Randomized Controlled Trials

Contact Info

Product

Resources

About